Prelude Therapeutics (PRLD) Enterprise Value (2019 - 2026)
Prelude Therapeutics (PRLD) reported Enterprise Value of -$144.6 million for Q1 2026, down 40.23% on a YoY basis from -$241.9 million in Q1 2025, and down 40.1% sequentially from -$103.2 million in Q4 2025.
Prelude Therapeutics (PRLD) Enterprise Value (2019 - 2026) Analysis & Trends
Prelude Therapeutics (PRLD) has 8 years of Enterprise Value data on file, last reported at -$144.6 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 40.23% year-over-year to -$144.6 million; the trailing twelve-month figure through Mar 2026 stood at -$144.6 million (down 40.23% YoY), and the FY2025 full-year result was -$103.2 million, up 25.02% from the prior year.
- Enterprise Value slipped to -$144.6 million in Q1 2026, from -$103.2 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$55.0 million in Q3 2025 to a low of -$270.2 million in Q1 2022.
- A 5-year average of -$181.0 million and a median of -$183.9 million in 2024 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value jumped 65.14% in 2025 and slumped 40.23% in 2026, its largest moves.
- Tracing PRLD's Enterprise Value over 5 years: stood at -$205.8 million in 2022, then fell by 15.17% to -$237.0 million in 2023, then jumped by 41.91% to -$137.7 million in 2024, then gained by 25.02% to -$103.2 million in 2025, then tumbled by 40.1% to -$144.6 million in 2026.
- Business Quant data shows PRLD's Enterprise Value at -$144.6 million in Q1 2026, -$103.2 million in Q4 2025, and -$55.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Prelude Therapeutics | 324.30 Mn | 179.71 Mn | - | -144.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -144.60 Mn |
| Dec 31, 2025 | -103.21 Mn |
| Sep 30, 2025 | -54.96 Mn |
| Jun 30, 2025 | -124.76 Mn |
| Mar 31, 2025 | -103.12 Mn |
| Dec 31, 2024 | -137.66 Mn |
| Sep 30, 2024 | -157.67 Mn |
| Jun 30, 2024 | -183.89 Mn |
| Mar 31, 2024 | -205.97 Mn |
| Dec 31, 2023 | -236.98 Mn |
| Sep 30, 2023 | -234.55 Mn |
| Jun 30, 2023 | -259.03 Mn |
| Mar 31, 2023 | -176.30 Mn |
| Dec 31, 2022 | -205.77 Mn |
| Sep 30, 2022 | -228.09 Mn |
| Jun 30, 2022 | -250.35 Mn |
| Mar 31, 2022 | -270.23 Mn |
| Dec 31, 2021 | -295.28 Mn |
| Sep 30, 2021 | -320.87 Mn |
| Jun 30, 2021 | -343.12 Mn |